SAGA Diagnostics® Launches Ultrasensitive Pathlight™ MRD Test in Colorectal Cancer
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
Abstract #518574: Ultrasensitive Structural Variant-based ctDNA detection of MRD in Colorectal Cancer – the CITCCA study
SAGA Diagnostics® Presents Real-World Pathlight™ MRD Data at ASCO GI 2026
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
Prevalence and dynamics of circulating tumor DNA among patients with triple-negative breast cancer undergoing preoperative systemic therapy with or without immunotherapy
Neo-N: three-year event-free survival (EFS) and overall survival (OS) and ultrasensitive ctDNA and tumor infiltrating lymphocyte (TIL) dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab
CATER-MRD: Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER+/HER2-negative Breast Cancer
CLAIRE: A Multicenter, Prospective Single-arm Phase II Study Evaluating Liquid Biopsy Guided Intensified Follow-up Surveillance in Patients with Intermediate to High-risk ER+/HER2-negative Early-stage Breast Cancer
Longitudinal ctDNA Tracking in Early and Recurrent Breast Cancer Using an Ultrasensitive Structural Variant-Based Assay: An Updated Analysis from the TRACER Study
SAGA Diagnostics’ Pathlight™ MRD Further Demonstrates Clinical Validity In TNBC Trials Presented at SABCS
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
SAGA Diagnostics Showcases New Pathlight MRD Data at SABCS 2025
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring